Moleculin Biotech Inc is a preclinical stage pharmaceutical company. The company is engaged in the development of anti-cancer drug candidates. Its drug development technologies include liposomal Annamycin, WP1122 and WP1066.
Stock Price Prediction
Update at 5:00pm EST
1.221 - 1.227
1.227 - 1.231
1.165 - 1.174
1.174 - 1.179
1.178 - 1.191
1.191 - 1.198
as of: 2019-09-16 4:30:42 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.MBRX has closed below upper band by 14.7%. Bollinger Bands are 63.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to MBRX's normal range. The bands have been in this narrow range for 85 bars. This is a sign that the market may be about to initiate a new trend.
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.